Page 1,962«..1020..1,9611,9621,9631,964..1,9701,980..»

Japanese team develops cardiac tissue sheet from human iPS cells

Posted: October 24, 2014 at 8:48 am

KYOTO A team of Japanese researchers has successfully created cardiac tissue sheets generated from human induced pluripotent stem cells, according to a study in the online British journal Scientific Reports.

The team said it is the first time iPS cells have produced an integrated cardiac tissue sheet that includes vascular cells as well as cardiac muscle cells and is close to real tissue in structure.

The stem cell team, led by Kyoto University professor Jun Yamashita, hopes the achievement will contribute to the development of new treatments for heart disease, because it has already found evidence that transplanting the sheets into mice with failing hearts improves in their cardiac condition.

The team used a protein called VEGF, which is related to the growth of blood vessels, as a replacement for the Dkk1 protein previously used to create cardiac muscle sheets from iPS cells.

As a result, iPS cells were simultaneously differentiated to become cardiac muscle cells, vascular mural cells, and the endothelial cells that line the interior surface of blood vessels. The cells were cultivated into a sheet about 1 cm in diameter.

Three-layer cardiac tissue sheets were then transplanted into nine mice with dead or damaged heart muscle caused by heart attacks. In four of the mice, blood vessels formed in the area where the sheets were transplanted, leading to improved cardiac function.

The weak point of iPS cells is that there is a risk of developing cancer, but the cells did not become cancerous within two months of transplantation, the team said.

About 72 percent of the cardiac tissue sheet was made of cardiac muscle cells, while 26 percent of it consisted of endothelial cells as well as vascular mural cells. But the sheet contained a small portion of cells that had not changed, leading the team to call attention to the possibility that a cancerous change might take place over the longer term.

Yamashita said in the study that he believed the new form of cardiac sheets attached well.

Oxygen and nourishment were able to reach cardiac muscle through blood because there were blood vessels, he said.

Originally posted here:
Japanese team develops cardiac tissue sheet from human iPS cells

Posted in Stem Cells | Comments Off on Japanese team develops cardiac tissue sheet from human iPS cells

107.26 /$ (5 p.m.)

Posted: October 24, 2014 at 8:47 am

KYOTO A team of Japanese researchers has successfully created cardiac tissue sheets generated from human induced pluripotent stem cells, according to a study in the online British journal Scientific Reports.

The team said it is the first time iPS cells have produced an integrated cardiac tissue sheet that includes vascular cells as well as cardiac muscle cells and is close to real tissue in structure.

The stem cell team, led by Kyoto University professor Jun Yamashita, hopes the achievement will contribute to the development of new treatments for heart disease, because it has already found evidence that transplanting the sheets into mice with failing hearts improves in their cardiac condition.

The team used a protein called VEGF, which is related to the growth of blood vessels, as a replacement for the Dkk1 protein previously used to create cardiac muscle sheets from iPS cells.

As a result, iPS cells were simultaneously differentiated to become cardiac muscle cells, vascular mural cells, and the endothelial cells that line the interior surface of blood vessels. The cells were cultivated into a sheet about 1 cm in diameter.

Three-layer cardiac tissue sheets were then transplanted into nine mice with dead or damaged heart muscle caused by heart attacks. In four of the mice, blood vessels formed in the area where the sheets were transplanted, leading to improved cardiac function.

The weak point of iPS cells is that there is a risk of developing cancer, but the cells did not become cancerous within two months of transplantation, the team said.

About 72 percent of the cardiac tissue sheet was made of cardiac muscle cells, while 26 percent of it consisted of endothelial cells as well as vascular mural cells. But the sheet contained a small portion of cells that had not changed, leading the team to call attention to the possibility that a cancerous change might take place over the longer term.

Yamashita said in the study that he believed the new form of cardiac sheets attached well.

Oxygen and nourishment were able to reach cardiac muscle through blood because there were blood vessels, he said.

Excerpt from:
107.26 /$ (5 p.m.)

Posted in Stem Cells | Comments Off on 107.26 /$ (5 p.m.)

Osiris – Company Presentation – Video

Posted: October 24, 2014 at 8:47 am


Osiris - Company Presentation
Presented by: Lode Debrabandere, Ph.D., CEO Through over 20 years of research, experience and understanding, Osiris Therapeutics has led the way in mesenchymal stem cell (MSC) science and ...

By: Alliance for Regenerative Medicine

See more here:
Osiris - Company Presentation - Video

Posted in Regenerative Medicine | Comments Off on Osiris – Company Presentation – Video

UCSD, other stem cell clinics get millions

Posted: October 24, 2014 at 8:41 am

UCSD oncologist/researcher Catriona Jamieson is principal investigator for the university's $8 million stem cell grant.

To speed up the quest to bring stem cell therapies to patients, a state agency on Thursday granted $8 million each to three academic medical centers pursuing "translational" work -- UC San Diego, UC Los Angeles and City of Hope in Duarte.

The California Institute for Regenerative Medicine voted 10-1 to fund the "alpha" stem cell clinics, which are intended to bring stem cell treatments to the public.

UC San Diego's proposal supports two stem cell-based clinical trials, both already underway. Catriona Jamieson, an oncologist at the university, is the principal investigator for the grant.

One, a treatment for Type 1 diabetes, was developed by San Diego's ViaCyte. The other, for spinal cord injuries, was developed by Geron of Menlo Park. Geron dropped the trial, but it was picked up by Neuralstem of Germantown, Md. In October, UCSD treated the first patient in the revived trial at the university's Sanford Stem Cell Clinical Center.

The stem cell agency, commonly called CIRM, has focused heavily on basic research since its founding by California voters in 2004. But in recent years, the public has become more anxious to see the fruits of $3 billion in bond money given to the agency reach patients. The "alpha" clinics funded Thursday are part of that effort.

Early optimism that treatments would be quickly available was disappointed, mainly because issues of safety had to be resolved first. Therapies that actually place cells in the body posed new risks, because as living things, cells grow and can migrate. Embryonic stem cells can form tumors. Viacyte and Neuralstem grow replacement tissues from embryonic stem cells, so they needed to show that no unconverted cells would accidentally be introduced into the patient.

Skepticism has also grown over the ethics of CIRM officials, mainly regarding conflicts of interests. Many CIRM board members are chosen from institutions that get funded -- a feature written into the agency by Prop. 71. CIRM has adopted reforms to limit board members from voting in matters where they have conflicts. But CIRM's previous president, Alan Trounson, caused more controversy when he joined the board of CIRM-funded Stemcells Inc, just one week after departing the agency.

CIRM President Randy Mills, who replaced Trounson earlier this year, has tried to quell the controversy with new standards to prevent officials like Trounson from appearing to cash in on their agency role. And he has worked with the governing board to rethink how the agency's remaining funds can be best spent.

CIRM has invested heavily in San Diego stem cell programs, most notably contributing $43 million to a $127 million "collaboratory" building across from the Salk Institute in La Jolla. The Sanford Consortium, as it's called, brings together researchers from five institutions: UCSD, the Salk Institute, The Scripps Research Institute, the Sanford-Burnham Medical Research Institute and the La Jolla Institute for Allergy & Immunology.

See more here:
UCSD, other stem cell clinics get millions

Posted in Cell Medicine | Comments Off on UCSD, other stem cell clinics get millions

UCLA and UCI Awarded $8M Grant to Launch Collaborative Stem Cell Clinic "Center of Excellence"

Posted: October 24, 2014 at 8:40 am

Contact Information

Available for logged-in reporters only

Newswise In a first-of-its-kind collaboration, the University of California, Los Angeles, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and University of California, Irvine Sue & Bill Gross Stem Cell Research Center received a five year $8M grant from the California Institute of Regenerative Medicine (CIRM), the states stem cell agency, to establish a CIRM Alpha Stem Cell Clinic center of excellence to conduct clinical trials for investigational stem cell therapies and provide critical resources and expertise in clinical research.

The $8M grant was one of three awarded today by CIRM as part of the CIRM Alpha Stem Cell Clinics (CASC) Network Initiative. The joint UCLA/UCI award under the direction of Dr. John Adams, a member of the UCLA Broad Stem Cell Research Center and professor in the department of orthopaedic surgery, will accelerate the implementation of clinical trials and delivery of stem cell therapies by providing world-class, state-of-the-art infrastructure to support clinical research.

CIRM grant reviewers lauded the UCLA/UCI Consortiums impressive and multidimensional team of experienced personnel that will expand access to patients, attracting national and international clinical trials and accelerating future trials in the pipeline.

The initial stem cell trials supported by the UCLA/UCI Alpha Stem Cell Clinic will be two UCLA projects using blood forming stem cells. The first trial will test a stem cell-based gene therapy for patients with bubble baby disease, also called severe combined immune deficiency (SCID), in which babies are born without an immune system. Under the direction of Dr. Donald Kohn, the clinical trial will use the babys own stem cells with an inserted gene modification to correct the defect and promote the creation of an immune system. The second clinical trial, under the direction of Dr. Antoni Ribas, will use patients own genetically modified blood-forming stem cells to engineer and promote an immune response to melanoma and sarcomas.

This CIRM Alpha Stem Cell Clinic grant is an important acknowledgement of our cutting-edge research and will help us to advance the design, testing and delivery of effective and safe stem cell-based therapies, said Dr. Owen Witte, professor and director of the Broad Stem Cell Research Center. The implementation of a standard of excellence in clinical research will improve healthcare and the lives of patients far beyond the longevity of individual trials.

Operating as part of the larger state-wide CIRM supported network, Alpha Stem Cell Clinics provide critical operational support to conduct clinical trials, with focused resources and expertise in stem cell-based clinical research including clinical operations support and patient care coordination personnel.

UCI has established a strong preclinical stem cell research program, and its vital to move ahead to the clinical testing phase, said Sidney Golub, director of UCIs Sue & Bill Gross Stem Cell Research Center. To advance treatments in this field, we all have to work together, and thats what the UCLA-UCI Alpha Stem Cell Clinic program represents.

About the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research

See the rest here:
UCLA and UCI Awarded $8M Grant to Launch Collaborative Stem Cell Clinic "Center of Excellence"

Posted in Stem Cell Therapy | Comments Off on UCLA and UCI Awarded $8M Grant to Launch Collaborative Stem Cell Clinic "Center of Excellence"

Portola volunteer firefighter battles leukemia

Posted: October 24, 2014 at 1:50 am

Staff Writer

10/23/2014

Lauri has been on leave from the Portola Fire Department since April, when she was diagnosed with acute leukemia.

Lauri is 67. One day last April, she was shopping with her sister and felt tightness in her chest. By evening it was intense pain. Blood tests at the emergency room showed leukemia.

The next five weeks were intense for Lauri. She spent those weeks at Renown Regional Medical Center in Reno getting chemotherapy and blood transfusions. Pete spent nearly every night with her.

Since then Lauri has spent seven days out of every 28 in outpatient chemotherapy. She has had several more whole blood and platelet transfusions.

She said she is feeling much better. But she still gets tired and has to stay away from sick people, as she lacks the antibodies to fight illness.

Lauris doctor at UC Davis, Mehrdad Abedi, has her on a waiting list for a stem cell or bone marrow transplant. He told her chemotherapy will eventually stop working to fight the illness.

The only thing that may save Lauri is a stem cell or bone marrow transplant.

Lauri and Pete owned a sign business in Sparks, Nevada, for 20 years. They have volunteered for Washoe County Search and Rescue since 2000.

Read the original post:
Portola volunteer firefighter battles leukemia

Posted in Nevada Stem Cells | Comments Off on Portola volunteer firefighter battles leukemia

Precise and programmable biological circuits

Posted: October 24, 2014 at 1:48 am

15 hours ago

A team led by ETH professor Yaakov Benenson has developed several new components for biological circuits. These components are key building blocks for constructing precisely functioning and programmable bio-computers.

Bio-engineers are working on the development of biological computers with the aim of designing small circuits made from biological material that can be integrated into cells to change their functions. In the future, such developments could enable cancer cells to be reprogrammed, thereby preventing them from dividing at an uncontrollable rate. Stem cells could likewise be reprogrammed into differentiated organ cells.

The researchers have not progressed that far yet. Although they have spent the past 20 years developing individual components and prototypes of biological computers, bio-computers today still differ significantly from their counterparts made of silicon, and bio-engineers still face several major obstacles.

A silicon chip, for example, computes with ones and zeros current is either flowing or not and it can switch between these states in the blink of an eye. In contrast, biological signals are less clear: in addition to 'signal' and 'no signal', there is a plethora of intermediate states with 'a little bit of signal'. This is a particular disadvantage for bio-computer components that serve as sensors for specific biomolecules and transmit the relevant signal. Sometimes, they also send an output signal if no input signal is present, and the problem becomes worse when several such components are connected consecutively in a circuit.

A biosensor that does not 'leak'

ETH doctoral candidate Nicolas Lapique from the group led by Yaakov Benenson, Professor of Synthetic Biology in the Department of Biosystems Science and Engineering at ETH Zurich in Basel, has now developed a biological circuit that controls the activity of individual sensor components using internal "timer". This circuit prevents a sensor from being active when not required by the system; when required, it can be activated via a control signal. The researchers recently published their work in the scientific journal Nature Chemical Biology.

To understand the underlying technology, it is important to know that these biological sensors consist of synthetic genes that are read by enzymes and converted into RNA and proteins. In the controllable biosensor developed by Lapique, the gene responsible for the output signal is not active in its basic state, as it is installed in the wrong orientation in the circuit DNA. The gene is activated via a special enzyme, a recombinase, which extracts the gene from the circuit DNA and reinstalls it in the correct orientation, making it active. "The input signals can be transmitted much more accurately than before thanks to the precise control over timing in the circuit," says Benenson.

To date, the researchers have tested the function of their activation-ready sensor in cell culture of human kidney and cancer cells. Nevertheless, they are already looking ahead to further developing the sensor so that it can be used in a more complex bio-computer that detects and kills cancer cells. These bio-computers will be designed to detect typical cancer molecules. If cancer markers are found in a cell, the circuit could, for example, activate a cellular suicide programme. Healthy cells without cancer markers would remain unaffected by this process.

Versatile signal converter developed

View original post here:
Precise and programmable biological circuits

Posted in Kansas Stem Cells | Comments Off on Precise and programmable biological circuits

Stem Cells, Regenerative Medicine and Policy Impediments to the New Future – Video

Posted: October 23, 2014 at 10:48 am


Stem Cells, Regenerative Medicine and Policy Impediments to the New Future
Oct. 21, 2014 Baker Institute nonresident scholar Deepak Srivastava explores the current and future potential of stem cells and regenerative medicine.

By: BakerInstitute

More here:
Stem Cells, Regenerative Medicine and Policy Impediments to the New Future - Video

Posted in Stem Cell Videos | Comments Off on Stem Cells, Regenerative Medicine and Policy Impediments to the New Future – Video

Oregon | Pet Stem Cell Therapy

Posted: October 23, 2014 at 7:52 am

Willamette Valley, Oregon and Southwest Washington (PRWEB) October 09, 2014

Local veterinary surgeon Dr. Scott Gustafson is seeking candidates to participate in an investigational study of donor stem cells for dogs with osteoarthritis. Dr. Gustafson has lectured nationally on stem cell therapy and has performed clinical stem cell therapy for seven years. The ultimate goal of this study is to determine if a single injection of donor stem cells into one or two arthritically affected joints can help reduce pain and inflammation in the treated joints.

Candidates for the current investigational study must be older than nine months, weigh more than five and a half pounds, have osteoarthritis of only one or two leg joints, have had pain or lameness for at least three months, and must not have cancer. Joints that will be included in the study and injected under anesthesia include hips, stifles, shoulders, and elbows. Dogs that may be considered must be in good health and undergo a diagnostic work up before qualifying for the study.

Dr. Gustafson and his team coordinate directly with your veterinarian to provide the most advanced veterinary care available. Surgery 4 Pets mobile surgery provides the highest level of care and surgical expertise to your pet, in the hospital of your primary care veterinarian.

In 2007 Dr. Gustafson was credentialed with Vet-Stem, Inc. in the use of Regenerative Veterinary Medicine for arthritis, ligament and tendon injuries, and joint. To date he has provided about 100 stem cell treatments for dogs.

For information about the study, please contact Michael Stewman at mwstew(at)gmail(dot)com

About Vet-Stem, Inc. Since its formation in 2002, Vet-Stem, Inc. has endeavored to improve the lives of animals through regenerative medicine. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem pioneered the use of regenerative stem cells for horses, dogs, and cats. In 2004 the first horse was treated with Vet-Stem Regenerative Cell Therapy. Ten years later Vet-Stem celebrated its 10,000th animal treated. As animal advocates, veterinarians, veterinary technicians, and cell biologists, the team at Vet-Stem tasks themselves with the responsibility of discovering, refining, and bringing to market innovative medical therapies that utilize the bodys own healing and regenerative cells.

Contact: Sue Harman Senior Manager, Clinical Trials Vet-Stem, Inc. 12860 Danielson Court, Suite B Poway, CA 92064 858-748-2004

Follow this link: Surgery 4 Pets Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis

See original here:
Oregon | Pet Stem Cell Therapy

Posted in Oregon Stem Cells | Comments Off on Oregon | Pet Stem Cell Therapy

stem cell – MDBIZNews – MDBIZNews – News of the growing …

Posted: October 23, 2014 at 7:50 am

By Nick Sohr, Managing Editor, MDBIZNews

Seven-year-old biotech firm Lentigen has found an unlikely ally in its effort to best some of the most debilitating diseases, viruses and genetic disorders.

The Gaithersburg company is using viruses to manufacture and deliver what it hopes are life-saving vaccines and therapies to patients suffering from AIDS, brain cancer and a host of other maladies.

Think about this as a disruptive technology, said Tim Ravenscroft, Lentigens CEO. Were not looking here at incremental improvements for patients. Were looking at disease cures and really transforming a lot of these diseases for patients. This is not like a slight improvement on an existing therapy. Were trying to really transform the way patients are managed.

The key to Lentigens approach is lentiviral vectors, viruses that the company cooks up from scratch to accomplish their goals.

These lentiviruses are a subset of retroviruses, which hijack cells and splice in segments of DNA to force the captive cells to reproduce the virus.

What these viruses biologically were designed to do, or evolved to do, is to enter cells and take over their genetic machinery to produce more of themselves, Ravenscroft said. Weve modified that ability so that they now do what we want them to do.

Diseases caused by single gene defects are great targets for Lentigens technology, Ravenscroft said.

The company is working on a therapy for hemophilia A. The genetic blood disorder leaves victims without enough of a protein essential to clotting and is treated now with regular injections to make up for the deficiency.

Lentigens therapy calls for stem cells to be extracted from a patient. The cells are exposed to a lentivirus of the companys design that enters the cells and inserts DNA that will allow the cells to produce the missing protein. The stem cells are then returned to the patient who, the company hopes, will be able to produce the protein on his own.

Go here to read the rest:
stem cell - MDBIZNews - MDBIZNews - News of the growing ...

Posted in Maryland Stem Cells | Comments Off on stem cell – MDBIZNews – MDBIZNews – News of the growing …

Page 1,962«..1020..1,9611,9621,9631,964..1,9701,980..»